Sung‐Soo Yoon

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 140 citations

Medicine, Hematology, Oncology +15

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Thomas Barbour, Marie Scully, Gema Ariceta et al. · Kidney International Reports · 2021 · 66 citations · Full text

Life Sciences, Hematology, Pharmacotherapy +17

Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia

June‐Won Cheong, Hyeoung‐Joon Kim, Kyoo‐Hyung Lee et al. · Transfusion · 2013 · 48 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

<scp>L</scp>‐ascorbic acid represses constitutive activation of NF‐κB and COX‐2 expression in human acute myeloid leukemia, HL‐60

Seong‐Su Han, Eun‐Ryeong Hahm, Sook J. Lee et al. · Journal of Cellular Biochemistry · 2004 · 48 citations

Life Sciences, Molecular Biology, Oncology +14